APA (7th ed.) Citation

Yazici, Y., McAlindon, T., Gibofsky, A., Lane, N., Lattermann, C., Skrepnik, N., . . . Hochberg, M. (2021). A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis and cartilage, 29(5), 654-666. https://doi.org/10.1016/j.joca.2021.02.004

Chicago Style (17th ed.) Citation

Yazici, Y., et al. "A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis." Osteoarthritis and Cartilage 29, no. 5 (2021): 654-666. https://doi.org/10.1016/j.joca.2021.02.004.

MLA (9th ed.) Citation

Yazici, Y., et al. "A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis." Osteoarthritis and Cartilage, vol. 29, no. 5, 2021, pp. 654-666, https://doi.org/10.1016/j.joca.2021.02.004.